Jaypirca First-Line CLL Approval Extends Pirtobrutinib to Untreated Patients

Eli Lilly has secured a Jaypirca first-line CLL approval from the U.S. Food and Drug Administration. The agency cleared pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have no known 17p deletion. The decision, announced on 2 October 2026, places the drug at the start of the treatment sequence rather than reserving it for patients whose disease has already progressed on a covalent BTK inhibitor.

Source: Eli Lilly and Company press release, 2 October 2026.

What the Jaypirca first-line CLL approval covers

The new indication covers Jaypirca (pirtobrutinib, 100 mg and 50 mg tablets) in adult patients with previously untreated CLL/SLL and no known 17p deletion. It is the third indication for the molecule in the United States.

Ad

Jaypirca is a highly selective inhibitor of Bruton tyrosine kinase (BTK) and the first and only approved non-covalent BTK inhibitor. Lilly states that it is 300 times more selective for BTK than 98% of other kinases tested in preclinical studies, and that it binds both wild-type and C481-mutated BTK. Patients take a 200 mg oral dose once daily, with or without food, until disease progression or unacceptable toxicity.

CLL accounts for roughly one-quarter of new leukemia cases in the United States, and about 22,760 people are expected to be diagnosed this year. A deletion in chromosome 17, which typically affects the TP53 tumor suppressor gene, is present in only about 5% to 8% of patients at first diagnosis, so Lilly estimates that 92% to 95% of people with CLL do not carry it.

“This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile,” said Jennifer A. Woyach, M.D., professor, hematologist-oncologist, and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. “Doctors can now consider pirtobrutinib for appropriate patients when initial therapy is needed, not just later in a patient’s treatment journey. Given the efficacy and tolerability of modern targeted therapies, coupled with factors like age or comorbidity, many people diagnosed with CLL or SLL today may only receive one or two lines of therapy, making initial treatment choices critically important.”

BRUIN CLL-313: the data behind the decision

The approval rests on the primary analysis of BRUIN CLL-313, a global, randomized, open-label Phase 3 study. It enrolled 282 patients and assigned them 1:1 to pirtobrutinib 200 mg once daily or bendamustine plus rituximab (BR). Results were presented at the American Society of Hematology Annual Meeting in December 2025 and published in the Journal of Clinical Oncology.

At a median follow-up of 28 months, independent review committee (IRC) assessed progression-free survival favored pirtobrutinib (n=141) over BR (n=141), with a hazard ratio of 0.20 (95% CI, 0.11-0.37; p<0.0001). Median progression-free survival had not been reached in the pirtobrutinib arm, against 33.5 months for BR. The IRC-assessed overall response rate was 94% (95% CI, 89-98) with pirtobrutinib, made up of 13% complete responses and 81% partial responses, and 81% (95% CI, 73-87) with BR, where 21% were complete responses and 60% partial responses.

BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine a non-covalent BTK inhibitor in patients with previously untreated CLL/SLL without 17p deletion.

Source: Eli Lilly and Company. Median follow-up 28 months.

Safety in previously untreated patients

Lilly states that the overall safety profile in BRUIN CLL-313, including the rate of atrial fibrillation or flutter, matched earlier trials across treatment settings. All-grade atrial fibrillation or flutter occurred in 1.4% of patients taking pirtobrutinib. Median duration of treatment was 32 months, and 92% of patients stayed on treatment for more than 24 months.

Adverse reactions led to dose reductions in 3.6% of patients and permanent discontinuation in 4.3%. Serious adverse reactions occurred in 28%, and the only serious reaction reported in 3% or more of patients was pneumonia, at 5%. Reactions in fewer than 10% of patients that Lilly flags as clinically relevant were pneumonia and headache. All-grade adverse reactions at 20% or above included upper respiratory tract infection (27%), rash (22%) and COVID-19 (21%). Laboratory abnormalities that worsened from baseline in 20% or more of patients included decreased neutrophil count (48%), increased bilirubin (30%), increased ALT (27%), decreased hemoglobin (24%) and increased sodium (20%).

Patients with significant cardiovascular disease, including uncontrolled or symptomatic arrhythmias, were excluded from the study. The label carries a cardiac arrhythmias warning and precaution.

Where Jaypirca now sits in the treatment sequence

The new indication extends a label that has moved steadily earlier in CLL. The FDA granted accelerated approval for relapsed or refractory CLL/SLL in December 2023, then converted that to a traditional approval in December 2025 when it added patients who had already been treated with a covalent BTK inhibitor. Jaypirca also holds an accelerated approval for relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor.

“This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit, this time as an initial treatment for certain previously untreated patients with CLL or SLL,” said Jacob Van Naarden, executive vice president and president of Lilly Oncology. “This milestone underscores Jaypirca’s versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca’s broad applicability as a meaningful treatment option for people with CLL or SLL.”

Guideline positioning has followed the label. Jaypirca is the only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network (NCCN), as a Category 2A option for treatment-naive adults with CLL/SLL without del(17p) and as a Category 1 preferred option for relapsed or refractory disease after a covalent BTK inhibitor.

Evidence gaps a payer will notice

Two features of the evidence base shape how the first-line indication will read outside the clinic. The comparator is chemoimmunotherapy: BRUIN CLL-313 measured pirtobrutinib against bendamustine plus rituximab, not against the covalent BTK inhibitors that hold much of the first-line market. Lilly states that no trial has compared Jaypirca with covalent BTK inhibitors to test the clinical significance of the different binding mechanisms. The primary endpoint is also progression-free survival. Overall survival sits among the secondary endpoints, and the release reports no overall survival result, so the survival effect of moving a non-covalent BTK inhibitor to first line remains unproven.

The response pattern adds a second question. Pirtobrutinib produced more responses than BR but fewer complete responses, 13% against 21%, and depth of response often weighs heavily with reviewers judging whether a new first-line option changes the course of the disease. Woyach’s point about treatment lines raises the stakes: if many patients receive only one or two lines of therapy, the choice made at diagnosis carries much of the lifetime value of treatment.

How far that value travels across health systems is a separate question. Oncology health technology assessment is already under pressure from high-cost therapies and immature data, and the first-line CLL setting is crowded. NICE’s record run of positive recommendations for blood cancer treatments in 2024 shows that a favourable recommendation does not by itself guarantee fast uptake, and Jaypirca joins a category where U.S. first-line options have been widening. Lilly has not published a price for the new indication, and the drug is taken continuously until progression rather than for a fixed course.

The BRUIN program and what comes next

Lilly is running four Phase 3 studies of pirtobrutinib across lines of CLL/SLL therapy. Only one of them, BRUIN CLL-313, has read out.

Source: Eli Lilly and Company.

BRUIN CLL-314 is the first head-to-head Phase 3 trial to compare a covalent and a non-covalent BTK inhibitor, and BRUIN CLL-322 is the first Phase 3 readout in CLL with a venetoclax-containing control arm. Together they will decide whether the first-line approval leads to a broader shift in how CLL is treated, or remains an option for the subset of patients who cannot take a covalent BTK inhibitor for long.